INSP · Inspire Medical Systems, Inc.

The thesis

Inspire Medical Systems has secured the coding decision it needed, yet revenue is still falling, so the third-quarter report after the close on 2 November 2026 settles whether the shares can hold their rebound. The shares closed at $71.07 on 21 October 2026, up from $66.69 on 8 October 2026 and above the $70.50 close of 25 September 2026.

The American Medical Association's CPT Editorial Panel approved new Category I codes for single-lead implantation, including the Inspire V system, according to the company's 1 October 2026 announcement. The codes take effect on 1 January 2028. The company expects the Centers for Medicare & Medicaid Services (CMS) to publish proposed payment values in July 2027 and final values in November 2027.

The narrative is maturing: the coding approval resolved on 1 October 2026, and attention has shifted to near-term revenue. The 14-day relative strength index (RSI), a momentum gauge, was 50.7 on 21 October 2026, against 29.2 on 8 October 2026. The oversold reading has cleared.

Bullish and bearish views on Inspire Medical Systems, Inc.

The bull case on Inspire Medical Systems, Inc. (INSP), in brief: The permanent coding path is approved. The bear case: Revenue is still falling.

Bull case

• The permanent coding path is approved. The company's 1 October 2026 release says the AMA panel created dedicated codes for single-lead devices. The risk that the panel would reject the proposal is gone.
• Full-year guidance was raised in August. The second-quarter release of 3 August 2026 set 2026 revenue guidance at $835 million to $875 million, raised from the prior outlook, and adjusted diluted earnings per share at $1.05 to $1.45.
• Gross margin is improving with Inspire V. Second-quarter 2026 gross margin was 85.5%, up 150 basis points, mainly from a higher mix of Inspire V sales (company earnings release, 3 August 2026).
• Brokers keep raising targets. Truist raised its target to $78 with a Hold rating on 14 October 2026. RBC raised its Sector Perform target to $75 on 1 October 2026, Stifel set $80 on 11 September 2026, and Freedom Capital Markets set $97 on 21 September 2026. The 21 October 2026 close of $71.07 sits below all four.

Bear case

• Revenue is still falling. Second-quarter 2026 revenue was $200.6 million, down 7.6% from $217.1 million a year earlier, driven mainly by U.S. revenue (company earnings release, 3 August 2026). No later revenue figure has been reported.
• The new codes arrive in 2028. The 1 January 2028 effective date means the approval does not repair near-term billing, and payment values stay undecided until CMS acts in 2027.
• Barclays is Underweight. Barclays initiated coverage on 7 October 2026 with an Underweight rating and a $65 target, below the 21 October 2026 close of $71.07.
• The release gave no third-quarter outlook. The 3 August 2026 release carried full-year guidance only, and said most restructuring actions under Project Horizon are expected to finish in the third quarter. Benzinga's consensus for third-quarter revenue is about $204.1 million, so the print has a clear bar to clear or miss.

Price setup

The adjusted close was $71.07 on 21 October 2026, 50.6% below the adjusted 52-week high of $143.99. The shares rose 44.5% over three months to that date. The close sits above the $70.50 close of 25 September 2026 and well above the $66.69 close of 8 October 2026.

Analyst targets bracket the price. Barclays' $65 is the low end, Truist's $78 and RBC's $75 sit near it, and Stifel's $80 and Freedom Capital Markets' $97 are higher. The $60 level in the invalidation condition is below the 8 October 2026 close.

Crowding evidence is mixed. The earnings date is 12 days after the latest close, and a 10 September Benzinga screen listed Inspire among health care names with RSI above 70. The RSI has since reset to 50.7. No insider transactions or filings are reported in the past month.

Catalysts, next 30 days

• ~2027-07 (est.): CMS proposed payment values. The company expects them for the new codes, which set what the approval is worth per procedure.

Elapsed catalysts

• 2 November 2026: third-quarter 2026 results. The company reports after the close, with a call at 5:00 p.m. Eastern. It is the first revenue figure since August. (passed 4d ago)

What would change the view

The case breaks if the third-quarter report on 2 November 2026 shows another year-over-year revenue decline that management again blames on coding or reimbursement, or if full-year guidance of $835 million to $875 million is cut. A daily close below $60 would also end it.

The case would strengthen if third-quarter revenue lands at or above the roughly $204.1 million Benzinga consensus and management describes the year-over-year decline as narrowing. CMS proposed values in July 2027 below current procedure payment would weaken the longer-term argument.

What it trades with

Inspire trades with medical device and sleep-apnea names that depend on reimbursement policy, and with small and mid-cap health care shares generally. Its moves since September have followed coding and analyst news more than market direction. Its closest comparisons are other single-product device makers facing payer prior-authorization programs.